Search
MLN2704
go.drugbank.com/drugs/DB06513InvestigationalA Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.
STC3141
go.drugbank.com/drugs/DB16475InvestigationalSTC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.
SR 121463
go.drugbank.com/drugs/DB05455InvestigationalIt is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).
Talacotuzumab
go.drugbank.com/drugs/DB14796InvestigationalIt is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission). … Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123.
Banoxantrone
go.drugbank.com/drugs/DB04975InvestigationalBanoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. … Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. [A3115]
Carbenoxolone
go.drugbank.com/drugs/DB02329ExperimentalAn agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. … Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]
RGN6024
go.drugbank.com/drugs/DB33059ExperimentalReglagene announced FDA orphan drug designation for glioblastoma in 2024. RGN6024 remains investigational and is not an approved drug. … cells, and suppresses tumor growth in glioblastoma xenograft models.
RO7300490
go.drugbank.com/drugs/DB17535InvestigationalRO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in … RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist.
GLB-001
go.drugbank.com/drugs/DB32795InvestigationalGLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).
SAR445136
go.drugbank.com/drugs/DB17708InvestigationalHbF production in erythrocytes (RBC). … SAR445136 is an investigational zinc finger nuclease gene-edited cell therapy.